Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

JS Hyams; MC Dubinsky; RN Baldassano; RB Colletti; S Cucchiara; Hankje Escher; W Faubion; J Fell; BD Gold; A Griffiths; S Koletzko; S Kugathasan; J Markowitz; FM Ruemmele; G Veereman; H Winter; N Masel; CR Shin; KZL Tang; M Thayu

doi:10.1053/j.gastro.2017.02.004

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

JS Hyams, MC Dubinsky, RN Baldassano, RB Colletti, S Cucchiara, Hankje Escher, W Faubion, J Fell, BD Gold, A Griffiths, S Koletzko, S Kugathasan, J Markowitz, FM Ruemmele, G Veereman, H Winter, N Masel, CR Shin, KZL Tang, M Thayu

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

129 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1901-+
Journal	Gastroenterology
Volume	152
Issue number	8
DOIs	https://doi.org/10.1053/j.gastro.2017.02.004
Publication status	Published - 2017

Access to Document

10.1053/j.gastro.2017.02.004

http://hdl.handle.net/1765/99934

Cite this

Hyams, JS., Dubinsky, MC., Baldassano, RN., Colletti, RB., Cucchiara, S., Escher, H., Faubion, W., Fell, J., Gold, BD., Griffiths, A., Koletzko, S., Kugathasan, S., Markowitz, J., Ruemmele, FM., Veereman, G., Winter, H., Masel, N., Shin, CR., Tang, KZL., & Thayu, M. (2017). Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology, 152(8), 1901-+. https://doi.org/10.1053/j.gastro.2017.02.004

@article{ca9ae8bd6a764e59b3e5ce653a15a944,

title = "Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease",

author = "JS Hyams and MC Dubinsky and RN Baldassano and RB Colletti and S Cucchiara and Hankje Escher and W Faubion and J Fell and BD Gold and A Griffiths and S Koletzko and S Kugathasan and J Markowitz and FM Ruemmele and G Veereman and H Winter and N Masel and CR Shin and KZL Tang and M Thayu",

year = "2017",

doi = "10.1053/j.gastro.2017.02.004",

language = "Undefined/Unknown",

volume = "152",

pages = "1901--+",

journal = "Gastroenterology",

issn = "0016-5085",

number = "8",

}

Hyams, JS, Dubinsky, MC, Baldassano, RN, Colletti, RB, Cucchiara, S, Escher, H, Faubion, W, Fell, J, Gold, BD, Griffiths, A, Koletzko, S, Kugathasan, S, Markowitz, J, Ruemmele, FM, Veereman, G, Winter, H, Masel, N, Shin, CR, Tang, KZL & Thayu, M 2017, 'Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease', Gastroenterology, vol. 152, no. 8, pp. 1901-+. https://doi.org/10.1053/j.gastro.2017.02.004

TY - JOUR

T1 - Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

AU - Hyams, JS

AU - Dubinsky, MC

AU - Baldassano, RN

AU - Colletti, RB

AU - Cucchiara, S

AU - Escher, Hankje

AU - Faubion, W

AU - Fell, J

AU - Gold, BD

AU - Griffiths, A

AU - Koletzko, S

AU - Kugathasan, S

AU - Markowitz, J

AU - Ruemmele, FM

AU - Veereman, G

AU - Winter, H

AU - Masel, N

AU - Shin, CR

AU - Tang, KZL

AU - Thayu, M

PY - 2017

Y1 - 2017

U2 - 10.1053/j.gastro.2017.02.004

DO - 10.1053/j.gastro.2017.02.004

M3 - Article

VL - 152

SP - 1901-+

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 8

ER -